Detalles de la búsqueda
1.
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
BMC Cancer
; 20(1): 232, 2020 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32188417
2.
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Oncologist
; 24(6): 743-e205, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30591548
3.
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(1): 87-100, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29223745
4.
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Oncologist
; 22(6): 648-654, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28432226
5.
Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.
Oncologist
; 21(11): 1298-1305, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27742906
6.
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Oncologist
; 20(3): 239-40, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25637379
7.
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Breast Cancer Res Treat
; 152(1): 57-65, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26012644
8.
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
J Clin Oncol
; 41(32): 4976-4981, 2023 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37748109
9.
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer.
Nucl Med Commun
; 43(2): 212-219, 2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022378
10.
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer.
Cancers (Basel)
; 14(23)2022 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36497351
11.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Breast Care (Basel)
; 15(1): 30-37, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32231495
12.
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.
Sci Rep
; 8(1): 4371, 2018 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29531247
13.
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(94): 36720-36721, 2018 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30613355
14.
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(77): 34639-34640, 2018 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30349655
15.
Progress with palbociclib in breast cancer: latest evidence and clinical considerations.
Ther Adv Med Oncol
; 9(2): 83-105, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28203301
16.
Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients.
Oncotarget
; 8(46): 81343-81349, 2017 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29113393
17.
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.
Oncotarget
; 8(10): 16642-16649, 2017 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28186965
18.
Sorafenib for the treatment of breast cancer.
Expert Opin Pharmacother
; 18(6): 621-630, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28335647
19.
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
Cancer Chemother Pharmacol
; 79(5): 863-871, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28341957
20.
Androgen receptor signaling pathways as a target for breast cancer treatment.
Endocr Relat Cancer
; 23(10): R485-98, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27528625